Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

1.

NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people.

Mayberry JF, Lobo A, Ford AC, Thomas A.

Aliment Pharmacol Ther. 2013 Jan;37(2):195-203. doi: 10.1111/apt.12102. Epub 2012 Nov 14.

PMID:
23151246
[PubMed - indexed for MEDLINE]
2.

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C.

Health Technol Assess. 2011 Feb;15(6):1-244. doi: 10.3310/hta15060. Review.

PMID:
21291629
[PubMed - indexed for MEDLINE]
Free Article
3.
4.

Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.

Loftus EV Jr, Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM.

Eur J Gastroenterol Hepatol. 2009 Nov;21(11):1302-9. doi: 10.1097/MEG.0b013e32832a8d71.

PMID:
19465858
[PubMed - indexed for MEDLINE]
5.

Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine in patients with Crohn's disease.

Markowitz JF.

Rev Gastroenterol Disord. 2003;3 Suppl 1:S23-9.

PMID:
12684586
[PubMed - indexed for MEDLINE]
6.

Azathioprine and 6 Mercaptopurine in postoperative maintenance of Crohn's disease remission: is no evidence of effect an evidence of no effect?

Mardini HE.

Gastroenterology. 2005 Jan;128(1):246-8; author reply 248-9. No abstract available.

PMID:
15633153
[PubMed - indexed for MEDLINE]
7.

Nutritional therapy versus 6-mercaptopurine as maintenance therapy in patients with Crohn's disease.

Hanai H, Iida T, Takeuchi K, Arai H, Arai O, Abe J, Tanaka T, Maruyama Y, Ikeya K, Sugimoto K, Nakamura T, Nakamura K, Watanabe F.

Dig Liver Dis. 2012 Aug;44(8):649-54. doi: 10.1016/j.dld.2012.03.007. Epub 2012 Apr 27.

PMID:
22542605
[PubMed - indexed for MEDLINE]
8.

Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates.

Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB.

Gut. 2010 Sep;59(9):1200-6. doi: 10.1136/gut.2009.202101. Epub 2010 Jul 21.

PMID:
20650924
[PubMed - indexed for MEDLINE]
9.

Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis.

Peyrin-Biroulet L, Deltenre P, Ardizzone S, D'Haens G, Hanauer SB, Herfarth H, Lémann M, Colombel JF.

Am J Gastroenterol. 2009 Aug;104(8):2089-96. doi: 10.1038/ajg.2009.301. Epub 2009 Jun 30. Review.

PMID:
19568226
[PubMed - indexed for MEDLINE]
10.

Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.

Yang H, Craig D, Epstein D, Bojke L, Light K, Bruce IN, Sculpher M, Woolacott N.

Pharmacoeconomics. 2012 Apr;30(4):257-70. doi: 10.2165/11595920-000000000-00000. Review.

PMID:
22283690
[PubMed - indexed for MEDLINE]
11.
12.

Use of 6-mercaptopurine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: pro.

Hyams JS.

Inflamm Bowel Dis. 2005 Feb;11(2):197-9. No abstract available.

PMID:
15677914
[PubMed - indexed for MEDLINE]
13.

Predictive factors of response of perianal Crohn's disease to azathioprine or 6-mercaptopurine.

Lecomte T, Contou JF, Beaugerie L, Carbonnel F, Cattan S, Gendre JP, Cosnes J.

Dis Colon Rectum. 2003 Nov;46(11):1469-75.

PMID:
14605564
[PubMed - indexed for MEDLINE]
14.

Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation.

Cummins E, Royle P, Snaith A, Greene A, Robertson L, McIntyre L, Waugh N.

Health Technol Assess. 2010 Feb;14(11):iii-iv, xi-xvi, 1-181. doi: 10.3310/hta14110. Review.

PMID:
20223123
[PubMed - indexed for MEDLINE]
Free Article
15.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905
[PubMed - indexed for MEDLINE]
16.

Use of azathioprine and 6MP in postoperative Crohn's: changing natural history or just along for the ride?

Velayos FS, Sandborn WJ.

Am J Gastroenterol. 2009 Aug;104(8):2097-9. doi: 10.1038/ajg.2009.306.

PMID:
19661939
[PubMed - indexed for MEDLINE]
17.

Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience.

Sprakes MB, Ford AC, Suares NC, Warren L, Greer D, Donnellan CF, Jennings JS, Everett SM, Hamlin PJ.

Aliment Pharmacol Ther. 2010 Dec;32(11-12):1357-63. doi: 10.1111/j.1365-2036.2010.04482.x. Epub 2010 Oct 7.

PMID:
21050238
[PubMed - indexed for MEDLINE]
18.

[Optimization of immunomodulatory treatment with azathioprine or 6-mercaptopurine in inflammatory bowel disease].

Bastida Paz G, Nos Mateu P, Aguas Peris M, Beltrán Niclós B, Rodríguez Soler M, Ponce García J.

Gastroenterol Hepatol. 2007 Nov;30(9):511-6. Spanish.

PMID:
17980127
[PubMed - indexed for MEDLINE]
19.

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

Bouhnik Y, Lémann M, Mary JY, Scemama G, Taï R, Matuchansky C, Modigliani R, Rambaud JC.

Lancet. 1996 Jan 27;347(8996):215-9.

PMID:
8551879
[PubMed - indexed for MEDLINE]
20.

Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease.

Ochsenkühn T, Göke B, Sackmann M.

Am J Gastroenterol. 2002 Aug;97(8):2022-5.

PMID:
12190171
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk